Answers are grounded in this paper and cite their sources.
Rational drug design utilizing available X-ray crystal structures of sialic acid analogues bound to the active site of influenza virus neuraminidase has led to the discovery of a series of potent carbocyclic influenza neuraminidase inhibitors. From this series, GS 4104 (oseltamivir, TAMIFLU ) has emerged as a promising antiviral for the treatment and prophylaxis of human influenza infection. This article will summarize the design, discovery, and development of oseltamivir as an oral therapeutic to treat influenza infection.
No takes yet. Share an insight, caveat, or question.
Lew et al. (2000) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: